Clearside Biomedical, Inc.: 10-Q filed 2016-11-14
What Clearside Biomedical, Inc. reported in its quarterly report filed 2016-11-14 (fiscal Q3 2016): 28 published measures, 70 facts as tagged in accession 0001564590-16-029242.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2016-11-14
- Fiscal period
- fiscal Q3 2016
- Accession
- 0001564590-16-029242 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Clearside Biomedical, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 57,771,000 | USD | |
| At 2015-12-31 | 21,055,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 10,833,000 | USD | |
| At 2015-12-31 | 10,400,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 46,938,000 | USD | |
| At 2015-12-31 | -36,659,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 36,876,000 | USD | |
| At 2015-12-31 | 20,283,000 | USD | |
| At 2015-09-30 | 4,186,000 | USD | |
| At 2014-12-31 | 8,269,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | -5,645,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -16,196,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | -3,475,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -12,469,000 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | 3,000 | USD | 274 |
| 2015-01-01 to 2015-09-30 | 8,000 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | -55,559,000 | USD | |
| At 2015-12-31 | -39,363,000 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 110,000 | USD | |
| At 2015-12-31 | 156,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | 776,000 | USD | 274 |
| 2015-01-01 to 2015-09-30 | 502,000 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | -5,306,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -15,841,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | -3,374,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -12,301,000 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 57,654,000 | USD | |
| At 2015-12-31 | 20,482,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 2,928,000 | USD | |
| At 2015-12-31 | 5,196,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 1,347,000 | USD | |
| At 2015-12-31 | 1,469,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | 5,311,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 16,356,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | 3,374,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 12,301,000 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | 3,682,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 12,484,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | 2,309,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 6,964,000 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 20,545,752 | shares | |
| At 2015-12-31 | 2,659,262 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 102,481,000 | USD | |
| At 2015-12-31 | 2,701,000 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | -5,000 | USD |
Long-term debt
Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 8,000,000 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 262,000 | USD | |
| At 2015-12-31 | 259,000 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 152,000 | USD | |
| At 2015-12-31 | 103,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 7,000 | USD | |
| At 2015-12-31 | 7,000 | USD |
Other noncurrent liabilities
Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 251,000 | USD | |
| At 2015-12-31 | 261,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 1,556,000 | USD | |
| At 2015-12-31 | 1,985,000 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | -5,650,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -16,201,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | -3,475,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -12,469,000 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | 1,629,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 3,872,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | 1,065,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 5,337,000 | USD | 273 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | 49,000 | USD | 274 |
| 2015-01-01 to 2015-09-30 | 45,000 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | -339,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -355,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | -101,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -168,000 | USD | 273 |
Inspect the source
- Entity
- Clearside Biomedical, Inc. / CIK 0001539029
- Captured
- SEC response SHA-256
a1437e2d374588cac8926bbfdba573de86fcfd157d10f28f6b263d180fc3d71b
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001539029.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))